Staff commitment to trauma care improves mortality and length of stay at a level I trauma center.

BACKGROUND: Optimizing human resources at trauma facilities may increase quality of care. The purpose of this study was to assess whether staffing changes within a Level I trauma center improved mortality and shortened length of stay (LOS) for trauma patients. METHODS: Mortality, hospital LOS, and intensive care unit LOS were evaluated during three time periods: trauma service coverage by in-house general surgery residents and attendings ("group 1"), the creation of a core trauma panel with in-house trauma surgeons ("group 2"), and the addition of physician assistants (PAs) to the core trauma panel ("group 3"). Logistic regression and chi tests were used to compare mortalities, and multiple linear regression, t-tests, and median tests were used to compare LOS. RESULTS: There were 15,297 adult patients with trauma included in the analysis. After adjustment for transfers-in, mechanism of injury, injury severity score, age, and head injury, the presence of in-house trauma surgeons (group 2) decreased the following compared with group 1: overall mortality (3.12% vs. 3.82%, p = 0.05), mortality in the severely injured (11.41% vs. 14.83%, p = 0.02), and median intensive care unit LOS (3.03 days vs. 3.40 days, p = 0.006). The introduction of PAs to the core trauma panel (group 3 vs. group 2) decreased overall mortality (2.80% vs. 3.76%, p = 0.05), and reduced mean and median hospital LOS (4.32 days vs. 4.69 days, p = 0.05; and 3.74 days vs. 3.88 days, p = 0.02, respectively). CONCLUSION: The presence of in-house core trauma surgeons and PAs improves management and outcome of critically injured trauma patients within a level I trauma center.

Reduced mortality at a community hospital trauma center: the impact of changing trauma level designation From II to I.

OBJECTIVE: To determine if a change in trauma designation from level II (L2) to level I (L1) in the same institution reduces mortality. DESIGN, SETTING, AND PATIENTS: A retrospective cohort study of all patients consecutively admitted to a community hospital trauma center. INTERVENTION: The upgrade to trauma L1 designation (January 1, 2003-March 31, 2007) (n = 7902) from trauma L2 designation (January 1, 1998-December 31, 2002) (n = 9511). MAIN OUTCOME MEASURES: Adjusted overall mortality and adjusted mortality for severely injured patients, patients with complications, and patients with severe sites of injury. RESULTS: After adjusting for age, sex, Injury Severity Score, mechanism of injury, hypotension on admission, respirations, and comorbidities, there was a significant decrease in overall mortality during L1 designation compared with L2 designation (2.50% vs 3.48%; P = .001). Severely injured patients (Injury Severity Score of >/= 15) admitted during an L1 trauma designation had a significant reduction in mortality compared with patients admitted during an L2 designation (8.99% vs 14.11%; P < .001). Patients admitted during an L1 designation with a severe head, chest, or abdominal or pelvic injury diagnosis had a significant decrease in mortality (9.96% vs 14.51% [P = .005], 7.14% vs 11.27% [P = .01], and 6.76% vs 17.05% [P = .002], respectively), as did patients who developed acute respiratory distress syndrome during their hospital stay (9.51% vs 26.87%; P = .02). CONCLUSION: The significant reduction in mortality of trauma patients with severe or specific injuries after the change to a higher trauma level designation may justify direct triage of these patients to L1 facilities, when available.

Commercial human albumin preparations for clinical use are immunosuppressive in vitro.

OBJECTIVE: We previously reported significant variations in oxidation status and molecular length among sources and lots of human serum albumin (HSA) commercial preparations intended for clinical use. In this report, we investigated what effect the presence of HSA products have on the immune response in vitro. DESIGN: Laboratory study. SETTING: Trauma research basic science laboratory. SUBJECTS: Activated human peripheral blood mononuclear cells. INTERVENTIONS: Six commercial HSA preparations were tested for their effect on cytokine release from activated human peripheral blood mononuclear cells (PBMCs) and T-lymphocytes. Mass spectrometry analysis of aspartyl-alanyl diketopiperazine (DA-DKP) content of HSA and percentage of HSA having lost its amino terminal dipeptide aspartyl alanyl (HSA-DA) were correlated. MEASUREMENTS AND MAIN RESULTS: Human PBMCs were cultured in the presence of six commercial HSA preparations and activated via the T-cell receptor complex. A cloned T-lymphocyte cell line, activated with specific antigen, was also cultured with both synthetic DA-DKP and small molecular weight extracts from the commercial HSA tested. Supernatants were quantified by enzyme-linked immunosorbent assay for interferon-gamma and tumor necrosis factor-alpha content. DA-DKP was extracted from HSA by centrifugal filters and quantified by anion exchange liquid chromatography coupled to negative electrospray ionization mass spectrometry. HSA species were determined by reverse phase liquid chromatography coupled to positive electrospray ionization, time of flight mass spectrometry. All HSA preparations significantly inhibited the in vitro production of interferon-gamma and tumor necrosis factor-alpha by activated PBMCs. DA-DKP was detected in all HSA sources at concentrations ranging between 42.0 and 79.6 microM. A synthetic form of DA-DKP possessed similar immunosuppressive qualities in a dose-dependent manner on T lymphocytes. CONCLUSIONS: DA-DKP was present in significant concentrations in all HSA sources tested and was partially responsible for the immunosuppressive effects of HSA on activated PBMCs and T-lymphocytes in vitro. In view of these findings, administering HSA to immunocompromised critically ill patients might be reevaluated.